Daniel Duffy, MD
Family Medicine · Cedarburg, WINPI 1235191511
Payments from drug & device makers
Across 497 payments — averaging $390.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$60K
- AbbVie$40K
- Lilly USA, LLC$30K
- Eisai Inc.$23K
- Johnson & Johnson$13K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$8K
- plus $20K from 29 others
What the payments were for
- Consulting fees$50,11926%
- Speaking & faculty fees$118,13661%
- Travel & lodging$18,1879%
- Food & beverage$7,1764%
- Education$3870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 62 | $59,797 |
| AbbVie(2 entities) | 114 | $40,484 |
| Lilly USA, LLC | 116 | $29,729 |
| Eisai Inc. | 44 | $22,702 |
| Johnson & Johnson | 32 | $12,936 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $7,867 |
| Eli Lilly | 6 | $6,902 |
| Sunovion Pharmaceuticals Inc. | 10 | $4,109 |
| Otsuka America Pharmaceutical, Inc. | 10 | $3,703 |
| Genentech USA, Inc. | 3 | $2,124 |
| Pfizer | 9 | $1,693 |
| Astellas Pharma US Inc | 5 | $388 |
| AstraZeneca | 9 | $329 |
| Novo Nordisk | 13 | $277 |
| Novartis | 5 | $160 |
| Amgen | 4 | $123 |
| Jazz Pharmaceuticals Inc. | 2 | $114 |
| Boehringer Ingelheim | 4 | $71 |
| GSK | 5 | $71 |
| Boston Scientific | 1 | $61 |
| Bausch Health US, LLC | 3 | $48 |
| Merck | 3 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $26 |
| Mylan Specialty L.p. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Gilead | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$194,005 in reported general payments places this provider in the 95th percentile of 1,482 family medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $164,159 |
| OzempicSemaglutide | 81 | $129,685 |
| JardianceEmpagliflozin | 95 | $84,606 |
| MounjaroTirzepatide | 57 | $76,566 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 84 | $59,262 |
| XareltoRivaroxaban | 37 | $55,100 |
| TrulicityDulaglutide | 33 | $44,336 |
| VraylarCariprazine Hcl | 34 | $40,221 |
| EntrestoSacubitril/Valsartan | 35 | $36,994 |
| MyrbetriqMirabegron | 29 | $36,038 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $31,161 |
| InvokanaCanagliflozin | 19 | $25,848 |
| FarxigaDapagliflozin Propanediol | 17 | $22,250 |
| LinzessLinaclotide | 13 | $19,616 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $19,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,693 | $164,159158 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $71 | $143,868179 claims |
| Novo NordiskOzempic | $277 | $129,68581 claims |
| Lilly USA, LLCMounjaro, Trulicity | $29,729 | $120,90290 claims |
| Johnson & JohnsonXarelto, Invokana | $12,936 | $80,94856 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix | $71 | $68,36594 claims |
| AbbVieVraylar, Linzess | $40,484 | $59,83747 claims |
| NovartisEntresto | $160 | $36,99435 claims |
| Astellas Pharma US IncMyrbetriq | $388 | $36,03829 claims |
| AstraZenecaFarxiga, Brilinta | $329 | $35,19135 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $35 | $8,18311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Cedarburg
- Taha El-ShahatMadison$15.6M
- Jonathan MeimanMadison$4.3M
- John AgaibyKenosha$4M
- John LaabsShawano$3.6M
- Jennifer ParsleyElk Mound$1.4M
- William PalinMilwaukee$693K
- Jonathan TemteMadison$542K
- Ryan AndrewsStevens Point$429K
- Tara DallDelafield$230K
- Mark JensonGreen Bay$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.